Acronyms of Clinical Trial Names: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1,116: | Line 1,116: | ||
| [[Coronary Angioplasty Versus Excisional Atherectomy Trial II]] | | [[Coronary Angioplasty Versus Excisional Atherectomy Trial II]] | ||
|- | |- | ||
| [CBT-CD]] | | [[CBT-CD]] | ||
| [[Cognitive Behavior Therapy For The Chronic Depressions]] | | [[Cognitive Behavior Therapy For The Chronic Depressions]] | ||
|- | |- | ||
| Line 1,189: | Line 1,189: | ||
|- | |- | ||
| [[CHS]] | | [[CHS]] | ||
| [[Cardiovascular Health | | [[Cardiovascular Health Study]] | ||
----- | |||
---- [[CHS]] | |||
---- [[Charleston Heart Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Community Health Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Congenital Heart Surgeons Society Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Coronary Heart Study]] | |||
|- | |- | ||
| [[CIAO]] | | [[CIAO]] | ||
| Line 1,201: | Line 1,213: | ||
|- | |- | ||
| [[CIBIS III]] | | [[CIBIS III]] | ||
| [[ | | [[The Cardiac Insufficiency Bisoprolol Study III]] | ||
|- | |- | ||
| [[CIDS]] | | [[CIDS]] | ||
| Line 1,220: | Line 1,232: | ||
| [[CLASS]] | | [[CLASS]] | ||
| [[Celecoxib (Celebrex) Long-Term Arthritis Safety Study]] | | [[Celecoxib (Celebrex) Long-Term Arthritis Safety Study]] | ||
|- | |- | ||
| [[CLASSICS]] | | [[CLASSICS]] | ||
| Line 1,234: | Line 1,243: | ||
|- | |- | ||
| [[CLEAR PLATELETS-2]] | | [[CLEAR PLATELETS-2]] | ||
| [[Clopidogrel With Eptifibatide To Arrest The Reactivity Of Platelets]] | | [[Clopidogrel With Eptifibatide To Arrest The Reactivity Of Platelets-2]] | ||
|- | |- | ||
| [[CLEERE]] | | [[CLEERE]] | ||
| Line 1,241: | Line 1,250: | ||
| [[COACH]] | | [[COACH]] | ||
| [[Coordinating Study Evaluating Outcomes Of Advising And Counseling In Heart Failure]] | | [[Coordinating Study Evaluating Outcomes Of Advising And Counseling In Heart Failure]] | ||
|- | |- | ||
| [[COAST]] | | [[COAST]] | ||
| Line 1,262: | Line 1,268: | ||
| [[COMBINE]] | | [[COMBINE]] | ||
| [[Combining Medications And Behavorial Interventions ]] | | [[Combining Medications And Behavorial Interventions ]] | ||
|- | |- | ||
| [[COMET]] | | [[COMET]] | ||
| Line 1,277: | Line 1,280: | ||
| [[COMMIT/CCS-2 – Metoprolol]] | | [[COMMIT/CCS-2 – Metoprolol]] | ||
| [[Randomized, Placebo-Controlled Trial Of Early Metoprolol In 46,000 Acute Myocardial Infarction Patients]] | | [[Randomized, Placebo-Controlled Trial Of Early Metoprolol In 46,000 Acute Myocardial Infarction Patients]] | ||
|- | |- | ||
| [[COMPANION]] | | [[COMPANION]] | ||
| Line 1,313: | Line 1,313: | ||
| [[CONVINCE]] | | [[CONVINCE]] | ||
| [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints Trial]] | | [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints Trial]] | ||
|- | |- | ||
| [[COOL]] | | [[COOL]] | ||
| Line 1,334: | Line 1,331: | ||
| [[COPERNICUS]] | | [[COPERNICUS]] | ||
| [[Effect Of Carvedilol On Survival In Severe Chronic Heart Failure]] | | [[Effect Of Carvedilol On Survival In Severe Chronic Heart Failure]] | ||
|- | |- | ||
| [[COPPA]] | | [[COPPA]] | ||
| Line 1,358: | Line 1,352: | ||
| [[COURAGE]] | | [[COURAGE]] | ||
| [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation ]] | | [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation ]] | ||
|- | |- | ||
| [[COURT]] | | [[COURT]] | ||
| [[Contrast Utilization In High Risk Patients Undergoing Ptca]] | | [[Contrast Utilization In High Risk Patients Undergoing Ptca]] | ||
|- | |- | ||
| [[C-PORT]] | | [[C-PORT]] | ||
| Line 1,400: | Line 1,388: | ||
| [[CRIS]] | | [[CRIS]] | ||
| [[A Controlled Trial Of Verapamil In Patients After Acute Myocardial Infarction: Results Of The Calcium, Antagonist Reinfarction Italian Study]] | | [[A Controlled Trial Of Verapamil In Patients After Acute Myocardial Infarction: Results Of The Calcium, Antagonist Reinfarction Italian Study]] | ||
|- | |- | ||
| [[CRUISE]] | | [[CRUISE]] | ||
Revision as of 21:20, 29 June 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
For other acronyms involved in clinical trials, click here
For detailed instructions on how to contribute to WikiDoc's Clinical Trials Wiki, click here